ACE and type 1 diabetes mellitus: This landmark trial, conducted by the Collaborative Study Group in the early 1990s, revealed significant reductions in albuminuria, and an increased likelihood of remission from nephrotic-range albuminuria (65), when individuals with type 1 diabetes were treated with the ACE (angiotensin-converting enzyme) inhibitor captopril.